Drug Trial Radar · NCT07768592
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD)
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
May 6, 2030
Study completion May 6, 2030
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Aug 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate proof of mechanism (POM) and long-term safety and tolerability of E2511 in participants with Early AD. The study consists of 2 parts. In Part A, participants will be randomly assigned to receive either E2511 or donepezil. In Part B, participants will receive E2511 only. Once Part A and Part B participants complete the Core Trial (which includes Pretreatment and Treatment phases) they will have the option to enter the Extension Phase where they will receive E2511 for 18 months.
Conditions
- Alzheimers Disease
Interventions
E2511Drug
E2511 oral tablets.
DonepezilDrug
Donepezil oral tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A (Core Trial): Change from Baseline in [11C]MK-6884 Positron Emission Tomography (PET) Using Non-Displaceable Binding Potential (BPND) at 14 DaysTime frame: Baseline up to Day 14
- Part A and B (Extension Phase): Number of Participants With Adverse Events (AEs)Time frame: Up to 91 weeks
- Part A and B (Extension Phase): Number of Participants With Clinically Significant Changes in Vital Sign ValuesTime frame: From Week 13 up to Week 91
- Part A and B (Extension Phase): Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) ValuesTime frame: From Week 13 up to Week 91
- Part A and B (Extension Phase): Number of Participants With Clinically Significant Changes in Physical ExamTime frame: From Week 13 up to Week 91
- Part A and B (Extension Phase): Number of Participants With Clinically Significant Changes in Neurological ExamTime frame: From Week 13 up to Week 91
- Part A and B (Extension Phase): Number of Participants With Clinically Significant Changes in Laboratory Safety Tests ValuesTime frame: From Week 13 up to Week 91
- Part A and B (Extension Phase): Number of Participants With Suicidality as Assessed by Columbia - Suicide Severity Rating Scale (C-SSRS)Time frame: Up to 91 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.